Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.

This study has been withdrawn prior to enrollment.
(Enrollment difficulties)
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00365027
First received: August 15, 2006
Last updated: September 3, 2015
Last verified: September 2015

August 15, 2006
September 3, 2015
Not Provided
Not Provided
  • Implantation rate per transfer
  • Pregnancy rate per embryo transfer
  • Implantation rate per IVF cycle
  • Pregnancy rate per IVF cycle
Same as current
Complete list of historical versions of study NCT00365027 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.
Not Provided
It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Ovarian Hyperstimulation Syndrome
  • Infertility Drugs
  • Female
Procedure: Delayed embryo transfer
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
Not Provided

Inclusion Criteria:

  • Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation

Exclusion Criteria:

  • Patient's refusal to participate
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00365027
5040706
Not Provided
Not Provided
Not Provided
Not Provided
HaEmek Medical Center, Israel
Not Provided
Study Chair: Eliezer Shalev HaE'mek medical center
HaEmek Medical Center, Israel
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP